Antenatal risk assessment screening for pregnancy abnormalities

Details Antenatal risk assessment screening for pregnancy abnormalities Antenatal risk assessment screening for pregnancy abnormalities

1995-08-07

2000-02-08

Saunders, David

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

435 794, 436 65, 436 86, 436 87, 436510, 436518, 436811, 436817, 705 2, G01N 3368

Patent

active

060226951

ABSTRACT:
Dimeric inhibin concentration can be used in the determination of the risk of a women carrying an unborn child affected by chromosomal abnormalities, e.g. Downs Syndrome. A method for antenatal screening for chromosomal abnormalities is carried out by measuring body fluid taken from a pregnant woman for the level of at least one marker or precursor or metabolite of the marker together with the gestational age of the woman are compared with reference values taken from women carrying fetuses with chromosomal abnormalities and/or women carrying normal fetuses, using dimeric inhibin as a marker. A second marker is the free beta subunit of human chorion gonadotropin. An apparatus for carrying out the method described comprises a computer with a means for comparing the values described.

REFERENCES:
patent: 4874693 (1989-10-01), Bogart
patent: 5716853 (1998-02-01), Cuckle et al.
Prenatal Diagnosis, vol. 12, 1992, Chichester, pp. 801-806, Van Lith et al; "Second trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome".
Journal of Endocrinology, vol. 129, No. 2, May, 1991, Bristol, pp. R9-R12, Knight et al.; "Development of a two-site immunoradiometric assay for dimeric inhibin . . . ".
Obstetrics & Gynecology, vol. 83, No. 5, May 1994, New York, NY, pp. 661-664, Van Lith et al.; "First trimester maternal serum immunoractive inhibin . . . ".
Prenatal Diagnosis, vol. 15, No. 4, Apr. 1995, Chichester, pp. 359-362, Wallace et al.; "Evaluation of maternal serum dimetric inhibin . . . ".
American Journal of Human Genetics, vol. 55, No. 3, (Supplment), Sep. 1994, Chicago, p. A9, Canick et al.; "Maternal serum dimeric inhibin is elevated in Down syndrome", Abstract 37.
E. M. Wallace et al, Clin. Endocrinol., 41, 483-486, 1994.
Cuckle et al, Brit. Jour. Obst. Gyn. 94, 387-402 (1987).
Groome et al, Jour. Immunol. Meth. 165, 167-176 (1993).
Schneyer et al., "Immunoractive Inhibin . . . Radioimmunoassay", J. Clin. Endocrinol. Metab., 70, 1208-12, 1990.
Lambert-Messerlian et al, "Human Follicular Fluid . . . Proteins", J. Clin. Endocrinology and Metabolism, 78, 443-9, 1994.
Burger, "Inhibin", Reproductive Medicine Reviews, 1, 1-20, 1992.
McLachlan et al, "Circulating Immunoreactive . . . Cycle", J. Clin. Endocrinology and Metabolism, 65, 954-61 1987.
McLachlan et al, "Circulating immunoactive . . . indiction", Fertil. Steril., 48, 1001-08, 1987.
Tovanabutra et al, "The relationship between . . . pregnancy", Clin.Endocrinology, 38, 101-7, 1993.
Spencer et al, "Elevated Levels . . . Syndrome", Anal. Clin, Biochem., 30, 219-20, 1993.
Cuckle et al, "Maternal Serum . . . Pregnancies", Prenatal Diagnosis, 14, 387-90, 1994.

Affiliated with

Also associated with

Rating

Antenatal risk assessment screening for pregnancy abnormalities does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antenatal risk assessment screening for pregnancy abnormalities, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antenatal risk assessment screening for pregnancy abnormalities will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1679917